Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.73 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10413058 | 0.92 | EGFR (0.85) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL4600830 | 0.92 | EGFR (0.85) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL4600832 | 0.92 | EGFR (0.85) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL28529867 | 0.85 | KDM4E (1.00) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL26825 | 0.85 | KDM4E (1.00) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL26826 | 0.85 | KDM4E (1.00) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL437568 | 0.85 | KDM4E (1.00) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL305982 | 0.84 | KDM4E (0.72) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL3009380 | 0.84 | KDM4E (0.72) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL305983 | 0.84 | KDM4E (0.72) | EGFRCISD1KDM4ESLC16A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274633-A2 | PAIN RELIEF COMPOUNDS | UNIVERSITÉ CLERMONT AUVERGNE (FR) | 2015-10-01 | — | — | US | claimed |
| US-20150038466-A1 | PAIN RELIEF COMPOUNDS | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE CLERMONT FERRAND (FR) | 2015-02-05 | — | — | US | claimed |
| EP-0403238-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1990-12-19 | — | — | EP | claimed |
| US-20150274633-A2 | PAIN RELIEF COMPOUNDS | UNIVERSITÉ CLERMONT AUVERGNE (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150038466-A1 | PAIN RELIEF COMPOUNDS | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE CLERMONT FERRAND (FR) | 2015-02-05 | — | — | US | disclosed |
| EP-0571198-B1 | Cosmetic composition containing hair-growth promoter | UNILEVER PLC (GB) | 1997-03-19 | — | — | EP | disclosed |
| EP-0572167-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1996-10-09 | — | — | EP | disclosed |
| US-5559092-A | HAIR GROWTH, GLUTAMINE DIPEPTIDE | CHESEBROUGH-POND'S USA CO. DIVISION OF CONOPCO, INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0490581-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1996-05-22 | — | — | EP | disclosed |
| EP-0517371-B1 | Hair growth composition containing citric acid esters | UNILEVER PLC (GB) | 1996-01-10 | — | — | EP | disclosed |
| EP-0580409-A2 | Cosmetic composition containing DOPA derivatives | UNILEVER PLC (GB) | 1994-01-26 | — | — | EP | disclosed |
| EP-0572167-A1 | Cosmestic composition | UNILEVER PLC (GB) | 1993-12-01 | — | — | EP | disclosed |
| EP-0571198-A1 | Cosmetic composition containing hair-growth promoter | UNILEVER PLC (GB) | 1993-11-24 | — | — | EP | disclosed |
| EP-0517371-A2 | Hair growth composition containing citric acid esters | UNILEVER PLC (GB) | 1992-12-09 | — | — | EP | disclosed |
| EP-0490581-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038466-A1 | PAIN RELIEF COMPOUNDS | OPRL1, OPRK1, TRPV1 | EGFR 4863/4885CISD1 4136/4885KDM4E 3622/4885 |
| US-20150274633-A2 | PAIN RELIEF COMPOUNDS | OPRL1, OPRK1, TRPV1 | EGFR 4863/4885CISD1 4136/4885KDM4E 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.